Open AccessIdentification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2.
Author(s) -
Leslie D. Cahan,
Reiko F. Irie,
Rajesh Singh,
Andrew Cassidenti,
James C. Paulson
Publication year - 1982
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.79.24.7629
Subject(s) - ganglioside , antigen , glycolipid , lymphoblast , cell culture , human brain , biology , microbiology and biotechnology , melanoma , neuroectodermal tumor , in vitro , antibody , immunology , biochemistry , cancer research , immunohistochemistry , genetics , neuroscience
Two monospecific human antibodies (anti-OFA-I-1 and anti-OFA-I-2) produced in vitro by lymphoblast cell lines originating from melanoma patients have been shown previously to recognize cell surface antigens (OFA-I-1 and OFA-I-2) on human tumors and fetal brain: OFA-I-1 is expressed on a variety of human tumors, while OFA-I-2 has been detected only on tumors of neuroectodermal origin. Evidence presented in this report suggests that the two antigens expressed by a cultured human melanoma cell line (M14) are chemically distinct and that OFA-I-2 is a cell surface glycolipid, ganglioside GD2: GalNAc beta 1 leads to 4 NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3 Gal beta 1 leads to 4Glc-ceramide.